Ruitao Lin

Has grant

Assistant Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Ruitao Lin is an Assistant Professor at the University of Texas MD Anderson Cancer Center in the United States. His research interests encompass Bayesian randomized clinical trials, dose optimization in cancer treatment, and wellness programs for healthcare staff. Dr. Lin has contributed significantly to the field with recent publications focusing on sample size determination, trial design considerations, and the pharmacodynamics of cancer therapies.

Recent Grants

Grant: Close

Bayesian Methods for Complex Precision Biotherapy Trials in Oncology

Open Date: 2021-09-15

Close Date: 2025-08-31

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (5)

Pavlos Msaouel

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Peter F Thall

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Andrew Chapple

Assistant Professor

LSU Health Sciences Center

UNITED STATES

View details

Xiaohan Chi

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ruitao Lin

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Drift Parameter Based Sample Size Determination in Multi‐Stage Bayesian Randomized Clinical Trials

Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials

A Virtual Wellness Program to Enhance Well-being for Pediatric Oncology Staff during the COVID-19 Pandemic

TODO: A Triple‐Outcome Double‐Criterion Optimal Design for Dose Monitoring‐and‐Optimization in Multi‐Dose Randomized Trials

Sample-size determination for decentralized clinical trials

COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies

A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes

Pharmacodynamic Activity of [18F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2-Mutated Breast Cancer Receiving Talazoparib

SFU: Surface-Free Utility-Based Design for Dose Optimization in Cancer Drug Combination Trials

Online bootstrap inference for the geometric median

Novel clinical trial designs with dose optimization to improve long-term outcomes

Local continual reassessment methods for dose finding and optimization in drug-combination trials

Bayesian single‐to‐double arm transition design using both short‐term and long‐term endpoints

Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma

BOB: Bayesian optimal design for biosimilar trials with co‐primary endpoints

TITE‐BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late‐onset toxicity and efficacy

Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials

An overview of the BOIN design and its current extensions for novel early-phase oncology trials

BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS

Collaborators (5)

Pavlos Msaouel

Peter F Thall

Andrew Chapple

Xiaohan Chi

Timothy Yap

Make your next move.